Practical applications of a formulation containing sodium butyrate, probiotics, and a prebiotic – for which patients should support for the intestinal barrier and microbiota be considered? Review article
Article Sidebar
Main Article Content
Abstract
The problem of microbiota disorders and intestinal barrier stability, discussed in recent years, raises the question of the indications for supplementation with probiotics, prebiotics, and sodium butyrate preparations. Its role in regenerating and maintaining the integrity of the intestinal barrier, and consequently, a favorable profile of bacteria colonizing it, is crucial for the proper functioning of the large intestine. Disturbances in this system lead to abnormalities in intestinal function, particularly disorders of the cerebrospinal axis (DGBI – disorders of gut-brain interaction according to the Rome V Criteria, formerly known as irritable bowel syndrome). Taking antibiotics for various indications or other medications in chronic therapy, which adversely affect the intestinal microbiota, is also significant. The most common clinical situations presented here outline some of the indications for the practical use of probiotics, prebiotics, and sodium butyrate.
Article Details
Copyright by Medical Education. All rights reserved.
References
2. Corsetti M, Ahin A, Lcy BE et al. Gastroenterologia. 2026; 170: 1261-82.
3. Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70: 1214-40.
4. Choi Y, Youn YH, Kang SJ et al. 2025 Seoul Consensus on clinical practice guidelines for irritable bowel syndrome. J Neurogastroenterol Motil. 2025; 31: 133-69.
5. Kindt S, Louis H, De Schepper H et al. Belgian consensus on irritable bowel syndrome. Acta Gastroenterol Belg. 2022; 85: 360-82.
6. Lembo A, Sultan S, Chang L et al. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022; 163: 137-51.
7. Goodoory VC, Khasawneh M, Black CJ et al. Efficacy of probiotics in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology. 2023; 165: 1206-18.
8. Palleja A, Mikkelsen KH, Forslund KS et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology. 2018; 3(11):1255-65.
9. Khan Z, Khan SK, Reyaz I et al. Effectiveness of rifaximin on the outcomes of irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2023; 15: e44807.
10. Zhang Y, Tu M, Long P et al. Efficacy of probiotics pretreatment in Helicobacter pylori eradication therapy: a systematic review and meta-analysis of clinical outcomes. Ann Med. 2025; 57(1): 2533431.
11. Berumen A, Edwinson AL, Grover M. Post-infection irritable bowel syndrome. Gastroenterol Clin North Am. 2021; 50: 445-61.
12. Nazarewska A, Lewandowski K, Kaniewska M et al. Irritable bowel syndrome following COVID-19: an underestimated consequence of SARS-CoV-2 infection. Pol Arch Intern Med. 2022; 132: 16323.
13. Lewandowski K, Kaniewska M, Rosołowski M et al. Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe? Prz Gastroenterol. 2022; 17(3): 219-26.
14. Parthasarathy G, Chen J, Chen X et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016; 150: 367-79.e1.
15. Karłowicz K, Lewandowski K, Tulewicz-Marti E et al. A comprehensive review of usefulness of sodium butyrate for the management of inflammatory bowel disease: from molecular mechanisms to clinical application. Prz Gastroenterol. 2026; 21(1): 29-37.